Quoin Pharmaceuticals (QNRX) investor relations material

Company overview and business model

• Focuses on developing and commercializing therapies for rare and orphan diseases with limited or no approved treatments, with lead product QRX003 targeting Netherton Syndrome and Peeling Skin Syndrome.

• QRX003 is in late-stage clinical trials in the US, Europe, and other regions, with FDA Rare Pediatric Disease and Orphan Drug Designations, and similar status from the European Medicines Agency.

• Pipeline includes QRX008 for scleroderma and topical rapamycin formulations for other rare diseases, with global licensing and research agreements in place.

• Commercialization strategy includes building sales infrastructure in key markets and establishing distribution partnerships in 61 countries outside core territories.

• No products have been commercialized and no revenue has been generated to date.

Financial performance and metrics

• Reported net loss of $8.96 million for 2024 and $8.69 million for 2023, with net loss per ADS of $(66.90) and $(337.47) respectively, after a 1-for-35 reverse split.

• As of November 3, 2025, 838,976 ADSs were outstanding, representing 29,364,180 Ordinary Shares.

• The company is classified as a smaller reporting company, allowing for reduced disclosure obligations.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of ADSs by selling shareholders.

• May receive up to $88.7 million if all Ordinary Warrants are exercised for cash; intended use includes operating expenses, R&D, clinical development of QRX003, advancing other pipeline programs, working capital, acquisitions, and capital expenditures.